These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788 [TBL] [Abstract][Full Text] [Related]
5. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Carr BI; Wang Z; Wang M; Cavallini A; D'Alessandro R; Refolo MG Cancer Biol Ther; 2011 Sep; 12(6):531-8. PubMed ID: 21734462 [TBL] [Abstract][Full Text] [Related]
6. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition. Zhang R; Lin XH; Ma M; Chen J; Chen J; Gao DM; Cui JF; Chen RX J Transl Med; 2018 Nov; 16(1):302. PubMed ID: 30400797 [TBL] [Abstract][Full Text] [Related]
7. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412 [TBL] [Abstract][Full Text] [Related]
9. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132 [TBL] [Abstract][Full Text] [Related]
10. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation. Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
13. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
14. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Liang Y; Chen J; Yu Q; Ji T; Zhang B; Xu J; Dai Y; Xie Y; Lin H; Liang X; Cai X Cancer Med; 2017 Dec; 6(12):2787-2795. PubMed ID: 29030911 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930 [TBL] [Abstract][Full Text] [Related]
17. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854 [TBL] [Abstract][Full Text] [Related]
18. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506 [TBL] [Abstract][Full Text] [Related]
19. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344 [TBL] [Abstract][Full Text] [Related]
20. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]